Evelo Story

Macroaxis Story

Evelo Biosciences Debt to Equity Ratio is quite stable at the moment as compared to the past year. The company's current value of Debt to Equity Ratio is estimated at 0.55. Tangible Assets Book Value per Share is expected to rise to 4.48 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (84.6 M). The essential goal of this thesis is to break down our current position on Evelo for institutional investors considering to short it. We will inspect why Evelo Biosciences institutional investors may still consider a stake in the business.

Published over a month ago

View all stories for Evelo Biosciences | View All Stories

Are Evelo (NASDAQ:EVLO) institutional investors starting to hold back?

Evelo Biosciences is OVERVALUED at 10.23 per share with modest projections ahead. Over 87.0% of Evelo Biosciences shares are held by institutions such as insurance companies. Institutional ownership of Evelo Biosciences refers to the amount of Evelo Biosciences equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Evelo, including its current ownership diagnostics.

How important is Evelo Biosciences's Liquidity

Evelo Biosciences financial leverage refers to using borrowed capital as a funding source to finance Evelo Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Evelo Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Evelo Biosciences's total debt and its cash.

How Evelo utilizes its cash?

To perform a cash flow analysis of Evelo Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Evelo Biosciences is receiving and how much cash it distributes out in a given period. The Evelo Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Evelo Biosciences Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (66.49 Million)

Acquisition by David Epstein of 15690 shares of Evelo Biosciences subject to Rule 16b-3

Legal trades by Evelo Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Evelo insider trading alert for grant of stock option (right to buy) by David Epstein, the corporate stakeholder, on 20th of December 2020. This event was filed by Evelo Biosciences Inc with SEC on 2019-06-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Evelo

Evelo Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evelo Biosciences independently to ensure intended market timing strategies are aligned with expectations about Evelo Biosciences volatility.

Returns Breakdown

	Return on Assets	(0.78)
	Return on Equity	(0.97)
	Return Capital	(3.48)

Will Evelo Biosciences latest rise continue?

Latest downside deviation is at 5.35. Evelo Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evelo Biosciences independently to ensure intended market timing strategies are aligned with expectations about Evelo Biosciences volatility.

Our Conclusion on Evelo Biosciences

Whereas some other companies under the biotechnology industry are still a bit expensive, Evelo Biosciences may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Evelo as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Evelo Biosciences.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Evelo Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC